Sulodexide: A Renewed Interest in This Glycosaminoglycan
Open Access
- 1 September 2006
- journal article
- review article
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 24 (3-4) , 214-226
Abstract
Glycosaminoglycans (GAGs) are the most abundant group of heteropolysaccharides found in the body. These long unbranched molecules contain a repeating disaccharide unit. GAGs are located primarily in the extracellular matrix or on the surface of cells. These molecules serve as lubricants in the joints while at the same time providing structural rigidity to cells. Sulodexide is a highly purified glycosaminoglycan composed of a fast mobility heparin fraction as well as dermatan sulfate. Sulodexide differs from other glycosaminoglycans, like heparin, by having a longer half‐life and a reduced effect on systemic clotting and bleeding. In addition, sulodexide demonstrates a lipolytic activity that is increased in comparison to heparin. Oral administration of sulodexide results in the release of tissue plasminogen activator and an increase in fibrinolytic activities. An increasing body of research has demonstrated the safety and efficacy of sulodexide in a wide range of vascular pathologies.Keywords
This publication has 65 references indexed in Scilit:
- A Study on the Safety, Efficacy, and Efficiency of Sulodexide Compared with Acenocoumarol in Secondary Prophylaxis in Patients with Deep Venous ThrombosisAngiology, 2006
- Sulodexide Attenuates Myocardial Ischemia/Reperfusion Injury and the Deposition of C-Reactive Protein in Areas of Infarction without Affecting HemostasisThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal RegistryAngiology, 2004
- Nephropathy in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 1999
- Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexideMedicinal Research Reviews, 1998
- Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injuryCardiovascular Research, 1995
- Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathyKidney International, 1994
- Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic ratsKidney International, 1992
- Relative Efficacy of Heparin and Related Glycosaminoglycans as Antithrombotic DrugsAnnals of the New York Academy of Sciences, 1989
- Studies of chemical and biologic properties of a fraction of sulodexide, a heparin-like glycosaminoglycanAtherosclerosis, 1986